Fig. 5

BCL-2 dependence is a causal function of drug sensitivity in cancer cells in vitro. A BH3-profiling performed following treatment with DPI (0.1 μM) or AA (0.05 μM) for 15 h for OCI-Ly3 cells (n = 3). B Delta CytC release between DPI/AA- and DMSO-treated OCI-Ly3 (CytC release % value of DPI/AA minus CytC release % value of DMSO) was calculated to reflect absolute changes in dependence to specific anti-apoptotic protein(s) for survival (n = 3). C Western blot analysis showing S70pBCL-2, BCL-2 and β-Actin levels of OCI-Ly3. D Cell viability by CellTiter-Glo® was measured for OCI-Ly3 following 2-h pre-treatment with DPI (0.1 μM) or AA (0.05 μM) and subsequent 48-h co-treatment with either doxorubicin (0.1 μM, n = 4), etoposide (0.1 μM, n = 4), ABT199 (VEN) (0.1 μM, n = 4) or ibrutinib (1 μM, n = 3). Tukey’s multiple comparisons test was used